Recent Investment Analysts’ Ratings Changes for GRIFOLS S A/S (GRFS)

A number of firms have modified their ratings and price targets on shares of GRIFOLS S A/S (NASDAQ: GRFS) recently:

  • 10/31/2018 – GRIFOLS S A/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
  • 10/30/2018 – GRIFOLS S A/S was upgraded by analysts at Santander from an “underperform” rating to a “hold” rating.
  • 10/30/2018 – GRIFOLS S A/S was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/17/2018 – GRIFOLS S A/S was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 10/11/2018 – GRIFOLS S A/S was upgraded by analysts at Berenberg Bank from a “hold” rating to a “buy” rating.
  • 10/3/2018 – GRIFOLS S A/S was downgraded by analysts at UBS Group AG from a “neutral” rating to a “sell” rating.
  • 10/2/2018 – GRIFOLS S A/S was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
  • 10/1/2018 – GRIFOLS S A/S had its price target lowered by analysts at Morgan Stanley from $22.00 to $20.00. They now have an “underweight” rating on the stock.
  • 9/19/2018 – GRIFOLS S A/S was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of NASDAQ:GRFS opened at $20.93 on Wednesday. GRIFOLS S A/S has a 52-week low of $17.47 and a 52-week high of $25.18. The company has a market capitalization of $14.46 billion, a PE ratio of 19.03, a PEG ratio of 1.48 and a beta of 1.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.90 and a quick ratio of 1.12.

A number of hedge funds have recently bought and sold shares of GRFS. SG Americas Securities LLC increased its position in GRIFOLS S A/S by 38,886.6% during the 2nd quarter. SG Americas Securities LLC now owns 3,001,189 shares of the biotechnology company’s stock valued at $64,526,000 after buying an additional 2,993,491 shares in the last quarter. First Trust Advisors LP increased its position in GRIFOLS S A/S by 85.7% during the 3rd quarter. First Trust Advisors LP now owns 4,634,749 shares of the biotechnology company’s stock valued at $99,045,000 after buying an additional 2,139,441 shares in the last quarter. Engadine Partners LLP increased its position in GRIFOLS S A/S by 18.0% during the 2nd quarter. Engadine Partners LLP now owns 2,906,319 shares of the biotechnology company’s stock valued at $62,486,000 after buying an additional 443,386 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in GRIFOLS S A/S during the 2nd quarter valued at approximately $7,967,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in GRIFOLS S A/S during the 2nd quarter valued at approximately $6,482,000. 21.35% of the stock is owned by institutional investors.

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Recommended Story: Return on Equity (ROE)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply